Police release video of hit-and-run crash in downtown Los Angeles as search for suspect continues
Police have released new video of a hit-and-run crash that left a motorcyclist with severe injuries in downtown Los Angeles in March.
They were dispatched to the intersection of Cesar E. Chavez Boulevard and Bunker Hill Avenue at around 8 p.m. after learning of the crash on March 23, according to a release from the Los Angeles Police Department.
Investigators learned that the driver of a Jeep Gladiator truck was traveling eastbound on Cesar E. Chavez and began to make a left turn onto Bunker Hill when they struck the motorcycle, which was heading westbound.
Video of the crash, which can be viewed on the LAPD YouTube channel, shows the moment of impact, which caused the victim to fly off their motorcycle onto the hood of the truck before ending up in the street.
The Jeep can then be seen heading in reverse before driving from the scene heading westbound on Cesar E. Chavez. Some onlookers held their arms out towards the driver but they still did not stop.
The victim, who hasn't been identified, was taken to a hospital for what police called severe injuries.
Anyone who knows more about the incident is asked to contact LAPD investigators at (213) 833-3713.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why
Oscar Health, Inc. (NYSE:OSCR) is one of the Oscar Health extended its winning streak to a fourth consecutive day on Friday, jumping 13.05 percent to close at $21.22 apiece as investor sentiment was influenced by the previous days' surge. During the shortened, four-day trading week, shares of Oscar Health, Inc. (NYSE:OSCR) already grew by 52 percent, with analysts pointing to meme trading as having buoyed its share prices. Additionally, investor sentiment was supported by a new proposal for Medicare that would allow individuals and employers to enroll in a new version called 'Part E.' A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. While this would heighten competition with private insurers such as Oscar Health, Inc. (NYSE:OSCR), the voluntary enrollment could potentially delay or prevent Medicare's sooner-than-expected insolvency. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
City officials: Bonner acting chief
CUMBERLAND — A local radio station's reports that the city's police chief was removed from his job are not accurate, Cumberland officials said. WCBC radio Thursday reported Cumberland Police Chief Chuck Ternent was 'out' and 'has been relieved of his duties.' In response to questions from the Cumberland Times-News Friday, City Administrator Jeff Silka said via statement that the radio station's reports and social media posts need 'correction and clarification' regarding Ternent's employment status. 'After 32 years of loyal service to the city of Cumberland and its citizens, Chief Ternent has, for some time, been contemplating retirement in order to pursue other career opportunities which have become available,' Silka said. 'Recently, Chief Ternent has been off work addressing some health issues,' he said. 'In his absence, Lt. Eric Bonner will serve as acting chief.' Background According to the city's website, Ternent holds a master's degree in management from Johns Hopkins University. Chuck Ternent mug CHUCK TERNENT He joined the Cumberland Police Department in 1992, served as a detective assigned to the Allegany County Combined Criminal Investigation Unit, became a sergeant in 2003 and over the years climbed the ranks to became police chief in 2020. In recent years, Ternent has been credited for securing outside funding for various needs, such as a $330,750 grant to support police activities including crime reduction patrols, targeted enforcement, intelligence gathering, apprehension of violent criminals and streamlining information sharing to address gang and drug trafficking. Bonner Bonner joined the department in 2002, according to the city's website. He is a 2003 graduate of the Eastern Shore Criminal Justice Academy, 2001 graduate of Fairmont State University with a bachelor's degree in criminal justice law enforcement and minor in sociology, and was employed by the Ocean City Police Department. Bonner is a 2005 graduate of the University of Maryland's Institute for Advanced Law Enforcement studies and a 2006 graduate of Castle's K-9 school in Carlisle, Pennsylvania. Bonner has served 'as a patrol officer, K-9 handler, corporal and sergeant,' according to the website. Burt Silka last month said because of confidentiality and privacy laws that deal with personnel, he could not comment on or confirm a report about police department Capt. James Burt. At that time, WCBC radio reported Burt was 'suspended from his duties.' James Burt Capt. James Burt Friday, Silka said Burt is 'currently employed' by the city. Burt served as patrol commander and administrative lieutenant, and won the department's Top Gun Award seven times during his career. 'He also attended and graduated from the United States Department of Justice Federal Bureau of Investigation — FBI National Academy — Class #275 — in 2019,' according to the website. Currently, Burt 'is the department's training coordinator,' according to the website.
